Pharmaco-Proteomic Study of Hydroxyurea-Induced Modifications in the Sickle Red Blood Cell Membrane Proteome

Abstract

Hydroxyurea (HU) is an effective oral drug for the management of homozygous sickle cell anemia (SS) in part because it increases fetal hemoglobin (HbF) levels within sickle red blood cells (RBCs) and thus reduces sickling. However, results from the Multicenter Study of HU suggested that clinical symptoms often improved before a significant increase in HbF levels occurred. This indicated that HU may be acting through the modification of additional cellular mechanisms that are yet to be identified. Hence, in this study, we focused on the analysis of the sickle RBC membrane proteome +/− HU treatment. 2D-DIGE (Two Dimensional Difference In-Gel Electrophoresis) technology and tandem mass spectrometry has been used to determine quantitative differences between sickle cell membrane proteins in the presence and absence of a clinically relevant concentration of HU. In vitro protein profiling of 13 sickle RBC membrane samples +/− 50 μM HU identified 10 statistically significant protein spots. Of these, the most remarkable class of proteins to show a statistically significant increase was the anti-oxidant enzymes—catalase, thioredoxin peroxidase and biliver-din reductase and the chaperonin containing TCP1 complex assisting in the folding of RBC cytoskeletal proteins. Interestingly, catalase immunoblots showed an increase in the acidic forms of the enzyme within sickle RBC membranes on incubation with 50 μM HU. We further identified this modification in catalase to be phosphorylation and demonstrated that HU exposed SS RBC membranes showed a 2-fold increase in tyrosine phosphorylation of catalase as compared to counterparts not exposed to HU. These results present an attractive model for HU-induced post-translational modification and potential activation of catalase in mature sickle RBCs. These findings also identify protein targets of HU other than fetal hemoglobin and enhance the understanding of the drug mechanism.

Get full access to this article

View all access options for this article.

References

Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anemia haemoglobin. Nature 178:792–794, 1956.

Rodgers GP. Overview of pathophysiology and rationale for treatment of sickle cell anemia. Semin Hematol 34:2–7, 1997.

Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, MacMahon RP, Bonds DR. Effect of hydroxyurea on the painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332:1317–1322, 1995.

Orringer EP, Blythe DS, Johnson A, Philips G Jr, Dover GJ, Parket JC. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia. Blood 78: 212–216, 1991.

Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. British J Haematol 109:322–327, 2000.

Ballas SK, Dover GJ, Charache S. Effect of hydroxyurea on rheological properties of sickle cell erythrocytes in vivo. Am J Hematol 67:151–156, 2001.

Kakhniashvili DG, Griko NB, Bulla LA Jr, Goodman SR. The proteomics of sickle cell disease: profiling of erythrocyte membrane proteins by 2D-DIGE and tandem mass spectrometry. Exp Biol Med 230:787–792, 2005.

Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: John Wiley, 1999.

Dudoit S, Shaffer JP, Boldrick JC. Multiple hypotheses testing in microarray experiments. Statistical Science 18:71–103, 2003.

10.

R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07–0, URL http://www.R-project.org. 2007.

11.

Kakhniashvili DG, Bulla LA Jr, Goodman SR. The human erythrocyte proteome: analysis by ion trap tandem mass spectrometry. Mol Cell Proteomics 3:501–509, 2004.

12.

Noguchi CT, Schechter AN, Rodgers GP. Sickle cell disease pathophysiology. Billieres Clin Haematol 6:57–91, 1993.

13.

Iyamu EW, Fasold H, Roa D, del Pilar Aguinaga M, Toshio A, Turner E. Hydroxyurea-induced oxidative damage of normal and sickle cell hemoglobins in vitro: amelioration by radical scavengers. J Clin Lab Anal 15:1–7, 2001.

14.

Eskenazi AE, Pinkas J, Whitin JC, Arguello F, Cohen HJ, Frantz CN. Role of antioxidant enzymes in the induction of increased experimental metastasis by hydroxyurea. J Natl Cancer Inst 85:711–721, 1993.

15.

Nagai T, Tarumoto T, Miyoshi T, Ohmine K, Muroi K, Komatsu N, Sassa S, Ozawa K. Oxidative stress is involved in hydroxyurea-induced erythroid differentiation. British J Haematol 121:657–661, 2003.

16.

Cao C, Leng Y, Kufe D. Catalase activity is regulated by c-abl and arg in the oxidative stress response. J Biol Chem 278:29667–29675, 2003.